Breadcrumb

Our Discoveries

India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration

In October 2023, India’s counterpart to the US Food and Drug Administration, the Central Drugs Standard Control Organization, approved NexCAR19, an effective, low-cost CAR-T cell therapy. The development of the therapy was made possible by a years-long collaborative journey between the Indian Institute of Technology Bombay and Tata Memorial Centre in Mumbai with NCI researchers at the NIH Clinical Center. As India’s first approved CAR-T cell therapy, the treatment will be manufactured in Mumbai and is affordable for many. 

Read More

Novel T cell stimulation technique drives potent anti-tumor response

Researchers combined an antibody with an immune-signaling molecule resulting in an agent called STAR0602. A version of the novel agent was designed for and tested in mice, which induced significant tumor shrinkage and increased survival across six different types of cancer while exhibiting little toxicity. The promising lab findings have prompted the launch of a clinical trial in people.

Read More